Ambit Biosciences
| Public Company | |
| Traded as | NASDAQ: AMBI |
| Website |
ambitbio |
|
Footnotes / references
| |
Ambit is an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases.[1]:3[n 1] As of March 2014, the company is based in San Diego, California and consists of a single facility.[1]:58 Ambit made an initial public offering in May 2013 and is listed on the NASDAQ exchange under the symbol "AMBI".[2][3]
Products
Ambit has no products on the market.[1]:29
As of March 2014, three products were under development, of which quizartinib was their lead drug candidate.[1]:3
Business model
As of March 2014, Ambit seeks to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics.[1]:3 Further, Ambit aims to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.[1]:3
Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.[4]
References
- 1 2 3 4 5 6 7 "Ambit Biosciences Corporation". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 20, 2014. Commission File Number:001-35919.
- ↑ Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
- ↑ "AMBI Stock Quote". NASDAQ. Retrieved April 5, 2014.
- ↑ Fidler, Ben (April 1, 2014). "Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. United States.
Notes
- ↑ The SEC 10K submission for 2013 indicates that the company is a "biopharmaceutical" company, which implies that they are primarily developing biopharmaceuticals; however their lead product is a small molecule therapeutic, calling into question the term used in the SEC submission.